Avalo Therapeutics
AVTX
8 hedge funds and large institutions have $690K invested in Avalo Therapeutics in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more funds holding
Funds holding: 4 → 8 (+4)
0% more ownership
Funds ownership: 0% → 0% (+0%)
77% less capital invested
Capital invested by funds: $2.94M → $690K (-$2.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$219K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$219K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$54.7K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$45.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$27.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$385K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $524K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $62K | +$219K | +24 | New |
|
|
VKH
3
Virtu KCG Holdings
New York
| $61K | +$219K | +24 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $16K | +$54.7K | +6 | New |
|
|
5
Commonwealth Equity Services
Waltham,
Massachusetts
| $11K | +$45.6K | +5 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $10K | +$27.4K | +3 | +300% |
|
|
TWA
7
TCI Wealth Advisors
Tucson,
Arizona
| $3K | – | – | – |
|
|
BFA
8
BlackRock Fund Advisors
San Francisco,
California
| $2K | +$9.12K | +1 | New |
|
|
AIM
9
Acrospire Investment Management
Chicago,
Illinois
| $1K | – | – | – |
|
|
PWAM
10
Park West Asset Management
San Francisco,
California
| – | -$385K | -32 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$2K | – | – |
|
AVTX Hedge Fund Activity: Q4 2016 in Review
8 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2016, worth a combined $690K — down 77% from $2.94M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AVTX positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $219K. The largest seller was Park West Asset Management, exiting entirely with an estimated $385K sold.
- 8 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2016, up from 4 in Q3 2016.
- Funds reported $690K of Avalo Therapeutics stock for Q4 2016, down 77% quarter-over-quarter.
- 5 funds opened new Avalo Therapeutics positions in Q4 2016 and 1 closed out, a net change of +4 holders.
- The largest Avalo Therapeutics buyer in Q4 2016 was Vanguard Group, an estimated $219K added.
- The largest Avalo Therapeutics seller in Q4 2016 was Park West Asset Management, an estimated $385K sold.
Based on aggregated 13F filings for Q4 2016.